Planned sale

Jazz Pharmaceuticals (JAZZ): Officer filed to sell ~$1.3M

Bruce C Cozadd, Officer at Jazz Pharmaceuticals, filed to sell ~$1.3M of Jazz Pharmaceuticals shares.

~$1.3M
planned to sell · 6,000 shares, around Nov 2, 2026
Planned for
Nov 2, 2026
Notice filed
Nov 2, 2026

What stands out in this filing

  • The planned sale is less than 0.01% of the company's shares outstanding.
  • How the shares were acquired, per the notice: Stock Option.
  • The notice says the shares were received as pay (stock awards or options).
  • Broker named on the notice: Merrill Lynch.
  • A Form 144 announces a sale; the Form 4 that follows shows whether it took place, at what price.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

The company's last weighty Form 8-K report up to this date: reported its results, the same day (Nov 2, 2026).

  1. InsiderDirector sold ~$1.5M of JAZZ shares in the open market
  2. InsiderCEO sold ~$486K of JAZZ shares in the open market
  3. InsiderOfficer sold ~$289K of JAZZ shares in the open market
  4. Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  5. InsiderDirector sold ~$1.38M of JAZZ shares in the open market
  6. Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “Company” ), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier of the selection and appointment of her successor or by June 30, 2027.”
  7. InsiderCEO sold ~$473K of JAZZ shares in the open market
  8. Company filing · Form 8-K · ResultsReported its results
  9. Company filing · Form 8-K · ResultsReported its results
  10. InsiderDirector sold ~$1.3M of JAZZ shares in the open market

What came next

  1. InsiderCEO sold ~$225K of JAZZ shares in the open market
  2. Insider · 1 personInsiders: 2 sales (~$327K)
  3. 5% stakeFMR LLC reported a passive stake (13G) of 8.6%
  4. Insider · 1 personInsiders: 4 sales (~$16.2M)
View the official recordSEC Form 144

How to read SEC Form 144

Form 144 is a notice that a company insider plans to sell shares. It is filed when the sell order is placed, so it announces a planned sale and does not prove that the sale took place.

Full guide: What is an SEC Form 144?

What else is on file for Jazz Pharmaceuticals

For Jazz Pharmaceuticals, OQRO holds 25 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JAZZ page.

How this filing works

Explore the data

Common questions

Which Jazz Pharmaceuticals (JAZZ) insider traded, and how much?

Bruce C Cozadd, Officer at Jazz Pharmaceuticals, filed to sell ~$1.3M of Jazz Pharmaceuticals shares. 6,000 shares, Form 144 notice of a planned sale.

When did it happen, and when was it made public?

Planned for: Nov 2, 2026. Notice filed: Nov 2, 2026.

What stands out in this filing?

The planned sale is less than 0.01% of the company's shares outstanding. How the shares were acquired, per the notice: Stock Option. The notice says the shares were received as pay (stock awards or options).

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 144, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Jazz Pharmaceuticals recently?

For Jazz Pharmaceuticals, OQRO holds 25 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the JAZZ page.

Does this mean JAZZ stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Jazz Pharmaceuticals

Everything OQRO holds on this company is on its JAZZ page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data